Literature DB >> 17625614

Gene therapy trials for the treatment of high-grade gliomas.

Adam M Sonabend1, Ilya V Ulasov, Maciej S Lesniak.   

Abstract

High-grade gliomas remain relatively resistant to current therapy. Local recurrence is a common feature and the majority of patients progress despite conventional therapy. One modality-gene therapy-has shown a lot of promise in early preclinical and clinical studies aimed at advancing the treatment of this disease. In this review, we provide a comprehensive overview of clinical trials involving gene therapy in the field of neuro-oncology. The use of different delivery vehicles, including liposomes, cells, and viruses, as well genes, especially cytokines and suicide genes, are explored in detail. The unique features and advantages/disadvantages of the different vectors employed are compared based on results of human studies. We discuss both the limitations and successes encountered in these clinical trials, with an emphasis on the lessons learned and potential ways of improving current gene therapy protocols.

Entities:  

Year:  2007        PMID: 17625614      PMCID: PMC1913943     

Source DB:  PubMed          Journal:  Gene Ther Mol Biol        ISSN: 1529-9120


  100 in total

1.  Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor.

Authors:  K Asaoka; M Tada; Y Sawamura; J Ikeda; H Abe
Journal:  J Neurosurg       Date:  2000-06       Impact factor: 5.115

2.  Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma.

Authors:  Juergen Voges; Regina Reszka; Axel Gossmann; Claus Dittmar; Raphaela Richter; Guido Garlip; Lutz Kracht; Heinz H Coenen; Volker Sturm; Karl Wienhard; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

3.  Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

Authors:  D W Andrews; M Resnicoff; A E Flanders; L Kenyon; M Curtis; G Merli; R Baserga; G Iliakis; R D Aiken
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.

Authors:  Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal
Journal:  Mol Ther       Date:  2005-10-28       Impact factor: 11.454

5.  Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

Authors:  L M Liau; K L Black; R M Prins; S N Sykes; P L DiPatre; T F Cloughesy; D P Becker; J M Bronstein
Journal:  J Neurosurg       Date:  1999-06       Impact factor: 5.115

6.  Epidemiologic study of primary intracranial neoplasms.

Authors:  J F Annegers; B S Schoenberg; H Okazaki; L T Kurland
Journal:  Arch Neurol       Date:  1981-04

7.  The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

Authors:  V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

Review 8.  Retroviruses as vectors.

Authors:  R G Vile; S J Russell
Journal:  Br Med Bull       Date:  1995-01       Impact factor: 4.291

9.  Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.

Authors:  Hideho Okada; Frank S Lieberman; Howard D Edington; Timothy F Witham; Mark J Wargo; Quan Cai; Elaine H Elder; Theresa L Whiteside; S Clifford Schold; Ian F Pollack
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 10.  Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.

Authors:  Amish C Shah; Dale Benos; G Yancey Gillespie; James M Markert
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

View more
  8 in total

1.  NEURO-ONCOLOGIC PHYSICAL THERAPY FOR THE OLDER PERSON.

Authors:  Willie Ching; Melissa Luhmann
Journal:  Top Geriatr Rehabil       Date:  2011-07-01

2.  FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.

Authors:  Ivy A Ho; Wai H Ng; Paula Y Lam
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

Review 3.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 4.  Stem cells as delivery vehicles for oncolytic adenoviral virotherapy.

Authors:  Justin Kranzler; Matthew A Tyler; Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

5.  Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells.

Authors:  Suvobroto Nandi; Ilya V Ulasov; Matthew A Tyler; Adam Quasar Sugihara; Luciana Molinero; Yu Han; Zeng B Zhu; Maciej S Lesniak
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

6.  Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.

Authors:  Ilya V Ulasov; Matthew A Tyler; Angel A Rivera; Dirk M Nettlebeck; Joanne T Douglas; Maciej S Lesniak
Journal:  J Med Virol       Date:  2008-09       Impact factor: 2.327

7.  Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.

Authors:  George E Naoum; Zeng B Zhu; Donald J Buchsbaum; David T Curiel; Waleed O Arafat
Journal:  Clin Transl Med       Date:  2017-03-01

Review 8.  Gene therapy for malignant glioma.

Authors:  Hidehiro Okura; Christian A Smith; James T Rutka
Journal:  Mol Cell Ther       Date:  2014-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.